Scoop: Gilead ter­mi­nates ear­ly-stage FLT3 tri­al in sol­id tu­mors

Gilead chopped a Phase Ib dose es­ca­la­tion study in re­cent days, with an up­date to the fed­er­al tri­als data­base say­ing the pre­ma­ture ter­mi­na­tion fol­lowed an “in­ter­nal safe­ty as­sess­ment.”

The IV-ad­min­is­tered FLT3 ag­o­nist, dubbed GS-3583, was be­ing test­ed as a monother­a­py in 13 pa­tients with ad­vanced sol­id tu­mors. The goal of the tri­al was to find out what dose to test in a Phase II, or max­i­mum tol­er­at­ed dose.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN